FKBP12
FKBP12 Molecule Information
Name:FK506-binding protein 1A
Target Synonym:FKBP12;12 kDa FKBP;FKBP-1A;FKBP1 ;FKBP1A;PPIase FKBP1A;Immunophilin FKBP12;Peptidyl-prolyl cis-trans isomerase FKBP1A;FKBP-12;Calstabin-1;FK506-binding protein 1A;Rotamase;12 kDa FK506-binding protein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved
FKBP12 Molecule Synonym Name
FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE
FKBP12 Molecule Background
Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.
FKBP12 References
FKBP12 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Tacrolimus Hydrate |
FK-506; FK-506E; FK-506MR; FR-900506; L-679934; MR-4; RTU-007; LCP-Tacro |
Approved |
Astellas |
PROGRAF |
fda |
|
ASTELLAS |
1994-04-08 |
Ulcerative colitis, Myasthenia, Lupus nephritis, Transplant rejection, Atopic dermatitis, Coronary restenosis, Rheumatoid arthritis (RA), Allergic conjunctivitis |
Details
|
FKBP12 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| Rimiducid |
AP-1903,AP1903 |
Phase Ⅱ |
Ariad, Bellicum |
Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) |
Details
|
A-Z
